Back to Awarded Treatment Trials
Awarded Trial: 02T-229
Grant ID
02T-229
Illness
Schizophrenia
Primary Drug/Intervention
Dehydroepiandrosterone (DHEA)
Primary Dosage
200mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Ritsner
Sample Size
62
Duration of Study Period for Each Subject
12 weeks
Outcome Measurements
PANSS, CANTAB, Quality of life
Results
There was a small, but significant difference between baseline and endpoint scores for DHEA treatment on PANSS total (3%), PANSS negative (13%) and PANSS positive (17%), but there was no significant difference between endpoint scores for placebo and DHEA. There were small, but significant benefits of DHEA on visual discrimination and visual attention. Qualify of life measures did not differ between groups.
Publication
N/A
Link
N/A
PI Name
Michael Ritsner
Degree
MD
Center
N/A
Institution
Sha'ar Menashe Mental Health Center
Address
Mobile Post Hefer 38814
City or Town
Hadera
State or Province
N/A
Zip or Postal Code
38814
Country
Israel
Email Address
ritsner@shaar-menashe.org.il